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ABSTRACT
Objective: Elevated serum ferritin has been linked to type 2 diabetes (T2D) and adverse health outcomes in subjects with the Metabolic
Syndrome (MetS). As the mechanisms underlying the negative impact of excess iron have so far remained elusive, we aimed to identify potential
links between iron homeostasis and metabolic pathways.
Methods: In a cross-sectional study, data were obtained from 163 patients, allocated to one of three groups: (1) lean, healthy controls (n¼ 53),
(2) MetS without hyperferritinemia (n ¼ 54) and (3) MetS with hyperferritinemia (n ¼ 56). An additional phlebotomy study included 29 patients
with biopsy-proven iron overload before and after iron removal. A detailed clinical and biochemical characterization was obtained and metab-
olomic proﬁling was performed via a targeted metabolomics approach.
Results: Subjects with MetS and elevated ferritin had higher fasting glucose (p < 0.001), HbA1c (p ¼ 0.035) and 1 h glucose in oral glucose
tolerance test (p¼ 0.002) compared to MetS subjects without iron overload, whereas other clinical and biochemical features of the MetS were not
different. The metabolomic study revealed signiﬁcant differences between MetS with high and low ferritin in the serum concentrations of
sarcosine, citrulline and particularly long-chain phosphatidylcholines. Methionine, glutamate, and long-chain phosphatidylcholines were
signiﬁcantly different before and after phlebotomy (p < 0.05 for all metabolites).
Conclusions: Our data suggest that high serum ferritin concentrations are linked to impaired glucose homeostasis in subjects with the MetS.
Iron excess is associated to distinct changes in the serum concentrations of phosphatidylcholine subsets. A pathway involving sarcosine and
citrulline also may be involved in iron-induced impairment of glucose metabolism.
 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. INTRODUCTION
Obesity is associated with type 2 diabetes (T2D) [1] and non-alcoholic
fatty liver disease (NAFLD) [2]. NAFLD has been linked to insulin
resistance (IR) and the Metabolic Syndrome (MetS) and is commonly
regarded as the hepatic manifestation of the MetS [3e5]. Different iron
phenotypes such as obesity-related iron deﬁciency as well as iron
overload have been observed in association with obesity [6]. Iron
overload linked to NAFLD is referred to as dysmetabolic iron overload
syndrome (DIOS) [6].
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Serum ferritin concentrations are commonly used in the clinical routine
as an indicator of body iron stores [7]. The MetS results in a complex
dysregulation of iron homeostasis [8]. Serum ferritin concentrations
increase with the number of features of the MetS [9] and several
studies have conﬁrmed the association between ferritin concentrations
and IR [10], body mass index (BMI) [11], visceral fat mass [12], blood
pressure [13], MetS [9,14], and polycystic ovary syndrome (PCOS)
[15]. In line with this, a high serum ferritin concentration has been
identiﬁed as a risk factor for the development of T2D and gestational
diabetes [16,17]. In morbidly obese subjects, ferritin strongly corre-
lated with waist circumference and IR. One year after gastric banding,
ferritin did not change signiﬁcantly despite weight loss and glucose
tolerance improvement. However, ferritin concentrations were still
correlated with IR at follow-up [18]. According to these observations,
ferritin concentrations may indicate pronounced IR in overweight or
obesity independent from other components of the MetS. Additionally,
the incidence of the MetS after 6 years was more than four-fold higher
in subjects with ferritin and transferrin in the highest tertile compared
with participants in the lowest tertile, suggesting prognostic relevance
[19]. In particular, serum ferritin concentrations may indicate more
severe hepatic IR and a higher risk for progression to relevant clinical
endpoints [20].
Since the role of iron overload in the pathogenesis of altered glucose
metabolism has so far been incompletely studied, we aimed to identify
potential metabolic pathways using a two-phased metabolomics
approach. First, subjects with MetS and iron excess were compared to
MetS subjects without iron excess and to control subjects; second, the
metabolomic changes in response to phlebotomy treatment were
investigated.
2. MATERIALS AND METHODS
2.1. Clinical and laboratory assessment
In a cross-sectional study, data were obtained from 163 patients,
allocated to one of three groups: (1) lean, healthy controls (n ¼ 53),
(2) MetS without iron overload (n ¼ 54) and (3) MetS with iron
overload (n ¼ 56). The second phlebotomy study included 29 pa-
tients with biopsy-proven iron overload before and after iron
removal. Subjects were recruited among patients of the First
Department of Internal Medicine, Paracelsus Medical University,
Salzburg, Austria, and the Department of Internal Medicine, Hospital
Oberndorf, Austria. In all subjects, an oral glucose tolerance test
(oGTT) with 75 g of glucose in 300 ml of water according to WHO
recommendations was performed [21]. The homeostasis model
assessment (HOMA-IR; fasting insulin [mU/L]  fasting glucose
[mmol/dL]/22.5) was used to calculate IR. T2D was classiﬁed as use
of diabetes medication or HbA1c  6.5% (48 mmol/mol) or
oGTT > 11.1 mmol/L (200 mg/dl) after 2 h or fasting
glucose > 7.0 mmol/L (126 mg/dl). Following an overnight fast,
venous blood was drawn. Full blood counts were obtained in all
subjects by standard laboratory methods. In addition, blood was
centrifuged, and plasma was analyzed for ferritin, transferrin and
serum iron content, serum transaminases (alanine aminotransferase
(ALT) and aspartate aminotransferase (AST)), gamma-glutamyl
transpeptidase (GGT), serum lipid proﬁle (including triglycerides,
total cholesterol, high-density lipoprotein cholesterol (HDL) and low-
density lipoprotein cholesterol (LDL)), glucose, insulin and C-reactive
protein (CRP), adiponectin, interleukin-6 (IL-6), tumor necrosis factor
a (TNFa), and leptin. HbA1c was quantiﬁed by HPLC using Adamts
H-8160 (Menarini, Florence, Italy). A standard physical examination
was performed that included blood pressure readings, BMI, and
waist and hip circumference. Blood pressure was taken by a nurse
and determined after a 5-min rest in a sitting position; the average
of two readings was used as the measurement of blood pressure.
Waist circumference was measured at the highest point of the iliac
crest with subjects standing in an upright position. BMI was
calculated as weight/height squared (kg/m2). Performance of liver
biopsy and assessment of iron deposition by Pearl’s stain was
described previously [22].
2.2. Deﬁnition of study groups
Subjects for the cross-sectional study were recruited from approxi-
mately 2563 participants of the population-based Salzburg Colon
Cancer Prevention Initiative (SAKKOPI study). The study design and
details of the clinical and biochemical work-up of included subjects
have been reported previously [23]. Subjects were allocated to one of
three groups: (1) lean, healthy control group (n¼ 53), (2) MetS without
iron overload (n ¼ 54) and (3) MetS with iron overload (n ¼ 56).
According to the “National Expert Panel on Detection, Evaluation, and
Treatment of High Blood Cholesterol in Adults” (NCEP-ATP-III) subjects
were considered to have MetS if at least 3 of the following 5 criteria are
present: waist circumference of more than 102 cm in men or more
than 88 cm in women, serum triglycerides of more than 150 mg/dL,
HDL-cholesterol below 40 mg/dL in men or below 50 mg/dL in women,
blood pressure of 130/85 mmHg or above, fasting plasma glucose of
more than 110 mg/dL (or a previous diagnosis of T2D) [24]. Iron
overload was deﬁned as serum ferritin values of 400e1100 ng/ml,
those subjects considered to have MetS without iron overload had
ferritin values from 30 to 120 ng/ml in men and women. Clinically
relevant active inﬂammation was excluded as a confounder of elevated
serum ferritin. Exclusion criteria were laboratory or clinical evidence of
autoimmune, viral (viral hepatitis, HIV), or hereditary causes (Wilson
disease, hereditary hemochromatosis, alpha-1 antitrypsin deﬁciency)
of liver disease, malignancy, and clinically relevant alcohol con-
sumption (>20 g per day for men and >10 g per day for women, a
limit considered to be below the traditional level for alcohol-induced
liver disease [25]).
Lean healthy control subjects had normal liver tests (ALT <35 IU/L for
men and <19 IU/L for women), no components of the MetS according
to NCEP-ATP-III criteria and normal biochemical iron parameters. The
control group was matched with the MetS groups according to gender
and age.
Throughout the study period, medication, especially lipid-lowering and
antihypertensive drugs, remained unchanged. None of the patients
was on insulin or oral antidiabetic therapy.
The study was approved by the local ethics committee (Ethikkom-
mission des Landes Salzburg, approval no. 415-E/1675/6-2013), and
informed consent was obtained from all participants.
2.3. Phlebotomies
Phlebotomies were performed biweekly until serum ferritin concen-
trations were between 50 and 100 mg/L. At every visit, serum ferritin
and hemoglobin concentrations were checked to assess therapeutic
efﬁcacy and to avoid anemia. In case of anemia or fatigue, the interval
was extended up to four weeks. Patients underwent 7.2 (5e12)
phlebotomies resulting in 3.7  2.8 g of removed iron per patient. Iron
removal was calculated by the amount of red blood count (RBC)
collected (1 ml of RBC ¼ 1 mg of iron).
2.4. Metabolomics
We performed a metabolomic proﬁling in all subjects. In the inter-
vention cohort, serum for the metabolomic analysis was drawn before
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the ﬁrst and 10e14 days after the ﬁnal phlebotomy. We used a tar-
geted metabolomics approach of combined direct ﬂow injection and
liquid chromatography MS/MS using the AbsoluteIDQTM p180 kit
(BIOCRATES life Sciences AG, Innsbruck, Austria) according to man-
ufacturers’ instructions. The methodological details are provided as
supplementary material and have been reported previously [26].
2.5. Statistical analysis
In the cross-sectional study, both the MetS cohorts (i.e. with and
without iron overload) was compared to the lean healthy control group.
Data were compared before and after phlebotomy. Analyses of clinical
and metabolic characteristics as well as graphic visualizations were
performed using the R statistics environment (version 3.2.1, R Foun-
dation for Statistical Computing, www.r-project.org) [27].
Metabolomics data was explored via principal component analysis
(PCA) and partial least squares discriminant analysis (PLS-DA) pro-
vided by the MetaboAnalyst webserver [28e30] to evaluate overall and
group-speciﬁc variances.
Concerning the cross-sectional study, group differences in de-
mographic, clinical, anthropometric, and laboratory characteristics
were assessed by Analysis of Variance (ANOVA) with Tukey’s HSD-post
hoc test for normally distributed data, KruskaleWallis test and Dunn’s
post-hoc analysis for non-normally distributed data, and chi-squared
test for qualitative variables. The corresponding metabolomics data
were logarithmized and analyzed using ANOVA with Tukey’s HSD-post
hoc test.
In the phlebotomy study, laboratory characteristics after phlebotomy
were compared to baseline values by Student’s t-test for normally
distributed and Wilcoxon rank-sum test for non-normally distributed
data, respectively. Metabolomics data of these subjects were loga-
rithmized and analyzed using paired Student’s t-test.
All p-values were adjusted for multiple testing using the Benjaminie
Hochberg principle [31] provided by the ‘metabolomics’-package [32]
for R. An adjusted p-value below 0.05 was considered statistically
signiﬁcant.
Multivariate linear regression analysis was performed to assess as-
sociations of metabolomic parameters with hyperferritinemia adjusting
for age, BMI, sex, ALT, oGTT 1 h and platelets.
3. RESULTS
3.1. Cross-sectional study e population 1
3.1.1. Clinical characteristics
Subjects with MetS with and without iron overload were studied in
order to identify clinical and metabolic differences related to iron;
additionally, healthy control subjects were assessed. The groups were
similar in age and sex distribution. According to the group deﬁnitions,
the control group and the groups with MetS differed in blood pressure,
lipids, liver enzymes, glucose homeostasis, and iron proﬁle. Subjects
with MetS were matched for their MetS components and only differed
in their iron proﬁles. Ferritin levels in the MetS group without iron
overload were signiﬁcantly and clinically relevant lower than in the
MetS group with iron overload (74.9  27.9 vs. 434.9  210.4 ng/ml,
p < 0.001). Differences between the two MetS groups were observed
regarding glucose parameters and liver enzymes. Subjects with MetS
and high ferritin had higher indices of impaired glucose homeostasis
as assessed by fasting glucose (97.6  17.2 vs. 107.3  15.1 mg/dl,
p < 0.001) and glucose concentration at 1 h in the oGTT
(152.9  41.1 vs. 184.0  46.1 mg/dl, p ¼ 0.002) compared to
subjects without iron overload. Likewise, patients with iron overload
had higher ALT (27.4 11.6 vs. 33.5 16.4 U/l, p¼ 0.077) and GGT
(37.8 32.3 vs. 53.9 68.5 U/l, p¼ 0.024) levels. However, the two
groups were similar in their lipid proﬁle, CRP, blood pressure, and BMI.
There were signiﬁcant differences in levels of adiponectin, IL-6, TNFa,
and leptin between the control group and those patients with MetS, but
no further differences between the subjects with and without iron
overload were noted. The clinical and biochemical characteristics are
summarized in Table 1.
3.1.2. Serum metabolomic analysis
Several results between MetS and healthy controls conﬁrmed previ-
ously reported differences. Thus, metabolite concentrations of sarco-
sine, alanine, glutamate, glycine, kynurenine, leucine, valine, and a
number of phosphatidylcholines (PC) were different between the
healthy control group and those with the MetS.
Comparison of subjects with high and normal iron parameters revealed
signiﬁcant differences in the serum concentrations of sarcosine,
citrulline, methioninsulfoxide, and, particularly, several long-chain PCs.
The detailed results of the metabolomic analysis in cross sectional
study comparing subjects with MetS with high and low ferritin are
shown in Table 2 and Figure 1.
3.2. Phlebotomy study e population 2
3.2.1. Clinical characteristics
In order to compare clinical and metabolic characteristics before and
after iron removal therapy, a phlebotomy intervention was performed in
a separate cohort. The population baseline characteristics were
comparable with the MetS group with iron overload (shown in Table 3).
Patients were overweight, most of them diagnosed with MetS, and had
pathological glucose homeostasis; all had high ferritin concentrations
and hepatic steatosis with mild to moderate iron deposition as
assessed by Pearl‘s stain on liver biopsy examination. We observed a
trend toward signiﬁcance for the reductions of ALT and GGT as pre-
viously reported in response to phlebotomy but no signiﬁcant differ-
ences were observed with regard to HOMA index, fasting glucose and
insulin, or lipid proﬁle.
3.2.2. Serum metabolomic analysis
Metabolomics proﬁling before and after phlebotomy identiﬁed a
number of signiﬁcant differences including methionine, glutamate,
and long-chain PCs. These changes are summarized in Table 4
and Figure 2. In order to identify metabolites related to iron sta-
tus, we looked for metabolites, which were both different between
the two MetS groups and also changed in response to iron
removal in the intervention study. Metabolites that fulﬁlled both
criteria were long-chain PCs including PC 40:2, PC 40:3, PC 40:4,
and PC 42:1, suggesting an interaction of iron status with the
homeostasis of these compounds. Univariate Spearman-rank
correlation analysis among subjects with the MetS revealed sig-
niﬁcant correlations for the above mentioned metabolomic analytes
with high ferritin concentrations and the clinical variables ALT,
platelets, oGTT 1 h. We then performed a multivariate regression
analysis that included these variables and found that after
adjustment for age, sex, ALT, platelets, and oGTT 1 h, only sar-
cosine and PC42_6, but not citrulline, PC32_2, PC38_4, PC40_2,
PC40_3, PC40_4, PC42_5, PC_E40_3, PC_E40_4, PC_E42_1
remained associated with high ferritin concentrations. None of
these variables was independently associated with clinical pa-
rameters before and after phlebotomy in the multivariate model in
the phlebotomy group (details not shown).
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4. DISCUSSION
In this two-phased study, we aimed to identify molecular links be-
tween iron status and metabolic changes in subjects with the MetS.
Clinically, subjects matched for age, sex and the presence of the
MetS were different with regard to indicators of impaired glucose
homeostasis. Although published data have linked higher iron stores
to other components of the MetS, our results suggest that iron may
be linked predominantly to impaired glucose homeostasis if subjects
with the MetS are compared. Epidemiologically, iron stores have
Table 1 e Cross-sectional study. Demographic, clinical, anthropometrical, and laboratory characteristics. Data are expressed as means and standard
deviations. p-values were assessed by Analysis of Variance (ANOVA) with Tukey’s HSD-post hoc test, KruskaleWallis test, and Dunn’s post-hoc analysis or chi-
squared test and adjusted for multiple comparison. Abbreviations: MetSeMetabolic Syndrome;Fee without iron overload;þFee with iron overload; BMIe
body mass index; WHR e waist hip ratio; GGT e gamma glutamyl transpeptidase; AST e aspartate aminotransferase; ALT e alanine aminotransferase; oGGT
e oral glucose tolerance test; HOMA e Homeostasis model assessment; Tchol e total cholesterol, HDL-C e high density lipoproteins, LDL-C e low density
lipoproteins, TGe triglyceride, CRPe C-reactive protein; ILe interleukin; TNFe tumor necrosis factor, ye years, kge kilogram, memeter, nge nanogram,
ml e milliliter, mg e milligram, dl e deciliter, mg e microgram, g e gram, U e unit, l e liter.
Lean healthy
n ¼ 53
MetSFe
n ¼ 54
MetSþFe
n ¼ 56
Adjusted P-value p
1 vs 2
p
1 vs 3
p
2 vs 3
Sex (male/female) 26/27 27/27 28/28
Age (y) 54.7  7.9 56.4  6.4 58.3  9.2 0.065
Systolic blood pressure (mmHg) 115.2  7,3 137.1  14.6 140.2  14.9 <0.001 <0.001 <0.001 0.446
Diastolic blood pressure (mmHg) 74.3  6.5 84.2  7.9 85.0  10.2 <0.001 <0.001 <0.001 0.783
BMI (kg/m2) 24.0  2.5 29.9  3.5 31.1  5.0 <0.001 <0.001 <0.001 0.497
WHR 0.91  0.07 0.96  0.06 0.99  0.07 <0.001 0.002 <0.001 0.039
Ferritin (ng/ml) 53.5  20.4 74.9  27.9 434.9  210.4 <0.001 0.008 <0.001 <0.001
Transferrin (mg/dl) 282.8  36.8 276.2  38.8 253.4  35.0 <0.001 0.638 <0.001 0.004
Transferrin saturation (%) 27.5  9.2 26.1  9.0 32.5  9.1 0.001 0.459 0.009 0.001
Serum iron (mg/dl) 108.3  34.5 99.8  32.2 115.6  33.7 0.058
Hemoglobin (g/dl) 14.5  1.2 14.7  1.7 15.2  1.0 0.008 0.131 0.005 0.131
GGT (U/l) 20.7  12.7 37.8  32.3 53.9  68.5 <0.001 <0.001 <0.001 0.024
AST (U/l) 20.9  6.4 23.2  7.0 26.6  10.9 0.005 0.100 0.003 0.144
ALT (U/l) 19.1  7.4 27.4  11.6 33.5  16.4 <0.001 <0.001 <0.001 0.077
Fasting plasma glucose (mg/dl) 92.8  7.7 97.6  17.2 107.3  15.1 <0.001 0.095 <0.001 <0.001
Fasting insulin (mU/ml) 5.6  3.0 13.0  15.1 13.5  7.1 <0.001 <0.001 <0.001 0.218
oGGT 1 h (mg/dl) 139.8  32.5 152.9  41.1 184.0  46.1 <0.001 0.295 <0.001 0.002
HbA1c (%) 5.4  0.4 5.5  0.3 5.7  0.4 0.001 0.441 <0.001 0.035
HOMA-IR 1.30  0.75 3.66  7.37 3.59  2.19 <0.001 <0.001 <0.001 0.106
Tchol (mg/dl) 219.5  37.6 230.7  47.0 238.6  53.0 0.103
HDL-C (mg/dl) 72.1  17.6 47.1  9.9 47.8  12.9 <0.001 <0.001 <0.001 0.962
LDL-C (mg/dl) 132.9  34.1 155.5  39.7 155.7  41.2 0.005 0.008 0.008 0.886
TG (mg/dl) 86.5  25.8 192.7  74.2 224.7  189.1 <0.001 <0.001 <0.001 0.702
CRP (mg/dl) 0.13  0.13 0.37  0.38 0.70  2.1 <0.001 <0.001 <0.001 0.319
Adiponectin (mg/ml) 13.6  4.2 10.4  4.1 10.2  3.7 <0.001 <0.001 <0.001 0.834
IL-6 (pg/ml) 2.9  1.2 4.1  2.2 5.9  10.6 <0.001 <0.001 <0.001 0.096
TNFa (pg/ml) 6.1  2.1 7.2  1.6 7.6  2.4 <0.001 0.003 0.001 0.737
Leptin (ng/ml) 5.9  4.2 19.9  16.9 20.3  12.8 <0.001 <0.001 <0.001 0.398
Table 2 e Cross-sectional study. Serum metabolome analysis. All concentrations are mM (micromole/L). Data are expressed as means and standard
deviations unless otherwise indicated. p-values were assessed by ANOVA with Tukey’s HSD-post hoc test and adjusted for multiple comparison. Abbreviations:
MetS e Metabolic Syndrome; MetSFe e Metabolic Syndrome without iron overload; MetSþFe e Metabolic Syndrome with iron overload; Met_So e
Methioninsulfoxide; PC e phosphatidylcholines, PC_E e plasmalogens.
Control MetSFe MetSþFe Adjusted p-value 1 vs 2 1 vs 3 2 vs 3
Sarcosine 5.71  1.72 9.06  4.55 18.74  16.3 <0.001 <0.001 <0.001 <0.001
Citrulline 36.03  7.14 33.55  7.05 29.39  7.51 <0.001 0.125 <0.001 0.001
Glutamate 60.04  31.59 83.61  30.39 96.25  34.43 <0.001 <0.001 <0.001 0.066
Met_So 1.07  0.57 1.20  0.97 1.84  1.77 0.014 0.656 0.002 0.007
Alanine 342.31  68.75 413.49  80.24 442.54  84.74 <0.001 <0.001 <0.001 0.062
Glycine 273.54  63.70 240.35  49.36 225.77  45.91 <0.001 0.003 <0.001 0.101
Kynurenine 2.57  0.56 3.35  0.75 3.60  0.97 <0.001 <0.001 <0.001 0.183
Leucine 141.24  31.32 167.87  28.86 168.53  41.52 <0.001 <0.001 <0.001 0.776
Valine 190.27  27.09 216.87  30.82 217.29  34.12 <0.001 <0.001 <0.001 0.995
PC_38_3 42.50  8.71 54.37  12.70 57.97  19.25 <0.001 <0.001 <0.001 0.335
PC_38_4 96.08  20.39 117.13  27.84 132.49  42.22 <0.001 <0.001 <0.001 0.052
PC_40_2 0.35  0.29 0.389  0.40 0.71  0.80 0.045 0.956 0.013 0.010
PC_40_3 0.72  0.31 0.81  0.46 1.02  0.61 0.015 0.325 0.001 0.020
PC_40_4 3.50  0.77 4.30  1.20 5.41  2.88 <0.001 0.001 <0.001 0.003
PC_42_5 0.40  0.11 0.41  0.14 0.53  0.21 0.001 0.681 <0.001 <0.001
PC_E30_0 0.53  0.14 0.46  0.15 0.42  0.10 0.001 0.002 <0.001 0.381
PC_E42_1 0.46  0.20 0.50  0.26 0.74  0.52 0.001 0.419 <0.001 0.002
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been positively associated with risk of T2D [33] and this ﬁnding was
later conﬁrmed in meta-analyses [34]. Liver iron, as measured by
magnetic resonance imaging (MRI), is positively associated with T2D
and IR [35]. Iron removal by phlebotomy has been associated with a
lower risk of T2D in previously non-diabetic individuals [36] and with
an improvement of IR in patients with MetS [37]. Unexpectedly, we
were not able to reproduce the well-recognized improvement of
glucose homeostasis in our phlebotomy study. Despite this fact, we
found an improvement of liver enzymes as an indicator of phlebotomy
effectiveness. We cannot exclude that some subjects did not adhere
to the dietary request of the study protocol (i.e. fasting state at time
of post-phlebotomy blood sample), which could limit the clinical
interpretation of the glucose parameters. We would ideally recom-
mend studying the effects of phlebotomy in the same subjects who
were also analyzed for group comparisons, which was not possible in
our study.
Excess iron in the liver causes hyperinsulinemia via decreased insulin
degradation and impaired insulin signaling [38]. The ensuing hyper-
insulinemic state may further augment the uptake of extracellular iron
by inducing the redistribution of transferrin receptors to the cell surface
[39] while downregulating hepcidin expression [40]. Additionally, cell
culture experiments have demonstrated that iron accumulation led to
IR and impaired glucose utilization in adipocytes [41]. Conversely, iron
chelation re-established insulin receptor signaling by increasing the
phosphorylation of forkhead transcription factor O1 (FoxO1), Akt/pro-
tein kinase B (Akt/PKB), and glycogen synthase kinase 3b (GSK3b),
which constitute key pathways for insulin’s effect on gluconeogenesis
and glycogen synthesis. Similarly, molecules of glucose utilization
such as glucose transporter 1 (GLUT1) or hypoxia-inducible factor 1a
(HIF1a) were increased in cultured hepatoma cells in response to iron
reduction resulting in glucose removal from the culture supernatant
[42]. Although these observations suggest that iron and glucose or lipid
homeostasis interact at the molecular level, data on the site of these
interactions have remained scarce in humans. Proﬁling of the serum
metabolome has been used as a valuable tool to identify subtle
changes in various diseases such as cancer, cardiovascular diseases,
or obesity [43e45].
We therefore reasoned that the association of metabolites with the
presence of iron in MetS and their changes in response to phlebotomy
may provide biochemical insight to pathways linked to the interaction
of iron homeostasis with IR. We identiﬁed several metabolite con-
centrations to be associated with the MetS. Sarcosine, alanine,
glutamate, glycine, kynurenine, leucine, valine and a number of PCs
were signiﬁcantly different between a healthy population and the two
MetS groups combined. These observed differences between healthy
subjects and the MetS widely conﬁrm published results [46e48],
which renders validity to our study results. The association of
metabolomic patterns with impaired glucose homeostasis could serve
to identify pathways involved in the development of T2D. Our data
suggest that sarcosine, alanine, glutamate, glycine, kynurenine,
branched-chain amino acids leucine and valine and a number of PCs
may be involved in the pathophysiology of the MetS. A role for plasma
Figure 1: Cross-sectional study. Serum concentrations of selected metabolites. All concentrations are mM (micromole/L). Each horizontal line denotes the p-value comparing
the respective groups by ANOVA. Abbreviations: MetS e Metabolic Syndrome; MetSFe e Metabolic Syndrome without iron overload; MetSþFe e Metabolic Syndrome with iron
overload, PC e phosphatidylcholine, PC_E e plasmalogens.
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branched-chain amino acids in T2D has been demonstrated previously
which is also supported by our ﬁndings [47].
The key aim of the study was to identify metabolic indicators linked to
higher iron status in subjects with the MetS. We found that the serum
concentrations of sarcosine, citrulline, methioninsulfoxide, and a
subset of long-chain PCs were signiﬁcantly different between the MetS
group with normal and high ferritin. For most metabolites in which
differences were observed, the high-iron phenotype was linked to a
further increase or decrease compared to the difference between
control subjects and low-iron MetS. These observations conﬁrm that
iron excess is related to a pronounced adverse metabolic derangement
in subjects with the MetS, which was particularly evident for sarcosine,
methioninsulfoxide, and a subset of long-chain PCs.
Since a high number of metabolites analyzed in metabolomics studies
increase the probability of identifying falsely positive results, we aimed
to reduce the number of false positives by additionally analyzing
changes in response to iron removal. We reasoned that this two-
phased approach would help identify metabolites truly linked to iron
status in the MetS, although potentially at the cost of missing me-
tabolites biologically linked to iron. This was especially and surprisingly
the case for several long-chain PCs, which so far have not been
implicated in iron homeostasis and implicated only marginally in the
pathophysiology of the MetS [49e52]. The interaction of ferritin and
PCs level could result from a direct inﬂuence of the liver iron on the
hepatic PCs production. Additionally, possible mechanisms include
changes of oxidative stress and subclinical inﬂammation in the case of
increased hepatic iron stores. In our study, levels of CRP and IL-6 were
not signiﬁcantly different between groups of MetS with and without
iron overload. However, there is a trend toward increased inﬂammation
with iron overload, and this might lead to changes in PCs levels.
Biosynthesis of PCs occurs via cytidine diphosphate (CDP)-choline and
phosphatidylethanolamine N-methyltransferase (PEMT) pathway, the
major site for the synthesis of PCs is the liver. PCs play a key role in
very low-density lipoproteins (VLDL) secretion, cell regeneration, and
membrane integrity [53e55]. In animal models of impaired PCs
biosynthesis, the impaired VLDL secretion resulted in an accumulation
of hepatic triglycerides [56e61], inducing the histological hallmark of
NAFLD. Additionally, PCs have an essential contribution to membrane
integrity, suggesting that higher serum concentrations could reﬂect
more advanced cell membrane damage. A pronounced decrease of
hepatic PCs levels lead to membrane damage and triggered a pro-
inﬂammatory cascade that further initiated progression to steatohe-
patitis [56,62].
Sarcosine is an intermediate of glycine biosynthesis and degradation. It
came into research focus recently as a new marker of prostate cancer
and its metastatic process [63e65]. Cleavage of glycine to sarcosine is
facilitated by glycine N-methyltransferase (GNMT) that is further
involved in gluconeogenesis [66,67]. Interestingly, sarcosine remained
independently associated after adjustment for clinical variables, which
suggests that its role in the MetS and DIOS should be studied further.
There is evidence for citrulline as a key regulator in lipid metabolism,
inﬂammation, and oxidative stress [68e71]. In addition, studies
support its role in skeletal muscle protein metabolism and its trophic
Table 3 e Phlebotomy study. Demographic, clinical,
anthropometrical, and laboratory characteristics. Data are expressed
as means and standard deviations unless otherwise indicated. p-values
were assessed by Student’s t-test or Wilcoxon rank-sum test and adjusted
for multiple comparison. Abbreviations: T2DM e type 2 diabetes mellitus,
BMI e body mass index; WHR e waist hip ratio; AST e aspartate
aminotransferase; ALT e alanine aminotransferase; GGT e gamma
glutamyl transpeptidase; HOMA e Homeostasis model assessment; Tchol
e total cholesterol, HDL-Ce high density lipoproteins, LDL-Ce low density
lipoproteins, TG e triglyceride, CRP e C-reactive protein; IL e interleukin;
TNF e tumor necrosis factor, y e years, kg e kilogram, m e meter, ng e
nanogram, mlemilliliter, mge milligram, dle deciliter, mge microgram,
g e gram, U e unit, l e liter.
Baseline
n ¼ 30
After
intervention
p-value
before/after
intervention
Sex (male/female) 28/2
Age (y) 56.1  7.4
T2DM n (%) 8 (26.7)
BMI (kg/m2) 29.6  2.5
Ferritin (ng/ml) 677.8  239.2 91.5  84.9 <0.001
Transferrin saturation (%) 35.2  10 20.8  9.8 <0.001
Hemoglobin (g/dl) 15.5  1 14.1  1.2 <0.001
AST (U/l) 42.6  14.3 43.3  16.2 0.839
ALT (U/l) 51.4  26.7 41.2  20.3 0.112
GGT (U/l) 117  87.1 111.5  84.9 0.632
Fasting plasma
glucose (mg/dl)
111.1  19 107.7  15.9 0.106
Fasting insulin (mU/ml) 23.2  12.8 21.7  10.7 0.536
HOMA-IR 6.8  4,2 6.1  3.6 0.615
Tchol (mg/dl) 212.4  42 200.2  39.8 0.097
HDL-C (mg/dl) 48.5  11.4 51.3  12.5 0.281
LDL-C (mg/dl) 129.1  36.2 119.2  32 0.228
TG (mg/dl) 222  128.3 196.3  97.7 0.318
IL-6 (pg/ml) 3.7  2 6.2  6.2 0.010
TNFa (pg/ml) 5.9  1.2 5.7  1 0.577
Leptin (ng/ml) 12.5  6.9 12.6  6.7 0.917
Table 4 e Phlebotomy study. Serum metabolome analysis before and
after phlebotomy. All concentrations are mM (micromole/L). Data are
expressed as means and standard deviations unless otherwise indicated. p-
values were assessed by paired Student’s t-test and adjusted for multiple
comparison. Abbreviations: Met_So e Methioninsulfoxide; PC e
phosphatidylcholine, PC_E plasmalogens.
Baseline After phlebotomy Adjusted p-value
Sarcosine 5.98  3.40 5.83  2.90 0.997
Citrulline 35.62  12.62 37.23  10.67 0.559
Glutamate 298.38  180.67 226.41  127.63 0.006
Methionine 22.24  9.84 28.90  9.05 0.006
Met_So 6.30  6.37 2.82  1.74 0.733
PC_36_0 2.50  1.17 1.79  0.90 0.002
PC_38_0 3.36  0.95 2.92  0.91 0.009
PC_38_1 2.50  1.27 1.95  0.72 0.006
PC_38_3 50.02 22.96 49.18 16.91 0.997
PC_38_4 123.18  56.31 120.46  36.78 0.988
PC_40_2 1.34  1.24 0.81  0.64 0.027
PC_40_3 1.24  0.90 0.83  0.52 0.006
PC_40_4 5.43  2.51 5.13  1.88 0.633
PC_42_0 0.61  0.25 0.50  0.19 0.008
PC_42_1 0.43  0.18 0.33  0.12 0.006
PC_42_4 0.55  0.42 0.39  0.26 0.004
PC_42_5 0.70  0.31 0.62  0.23 0.223
PC_E30_0 0.35  0.13 0.33  0.11 0.671
PC_E36_1 11.90  7.85 8.64  4.78 0.001
PC_E38_1 4.81  4.61 3.02  2.89 0.002
PC_E38_2 6.32  5.15 4.39  3.30 0.006
PC_E38_3 12.12  8.58 8.83  5.84 0.001
PC_E40_1 2.10  0.86 1.78  0.59 0.040
PC_E40_2 2.83  1.56 2.13  1.13 0.002
PC_E40_3 5.23  4.53 3.51  2.84 0.002
PC_E40_4 4.37  2.54 3.52  1.85 0.004
PC_E40_5 6.36  3.50 5.12  2.41 0.002
PC_E42_1 0.90  0.65 0.61  0.35 0.004
PC_E44_3 0.28  0.22 0.19  0.15 0.002
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effect on the gut [70,72]. Recent ﬁndings indicate that citrulline may
offer a therapeutic strategy for NAFLD [68,69]. Citrulline is produced in
the urea cycle mainly from ornithine and carbamoyl phosphate [73].
The urea and glutamate cycles are linked by aspartate. Despite this
connection, it is unclear if serum citrulline concentrations are inﬂu-
enced by these pathways in healthy humans. Recent data on the effect
of a glucagon-like peptide 2 analog give evidence that citrulline levels
are mainly determined by enterocyte mass. Hence, higher citrulline
concentrations may also indicate enhanced enterocyte mass and,
therefore, may represent a non-causative association with higher
ferritin concentrations [74].
Even if the population of the phlebotomy study is similar to the cohort
with MetS and iron overload regarding the criteria of MetS, the baseline
concentrations of metabolites differ. The reason for the difference is
speculative but might be the higher baseline ferritin concentrations and
the relevant higher insulin resistance in the cohort that underwent
phlebotomies. As the precise biochemical pathways between metab-
olomics changes on the one side and iron overload and glucose
metabolism on the other side is not clear, the ranked importance of
PCs, citrulline, and sarcosine will require further research. Neverthe-
less, our data strongly suggest that iron may interact with human
intermediary metabolism in multiple, so far unrecognized, biochemical
pathways beyond the known interactions with insulin receptor
signaling, gluconeogenesis, and adipokines. Our data, particularly on
ferritin and PCs, citrulline, and sarcosine, may also indicate that some
mechanisms play a role in certain subgroups of patients with the MetS.
In addition, the metabolomics changes could reﬂect different patho-
physiological pathways of hyperferritinemia and the altered glucose
metabolism in these patients.
In summary, our data conﬁrm that high serum ferritin concentrations
are linked to impaired glucose homeostasis. Additionally, our study
identiﬁes novel associations of iron excess in MetS subjects with
distinct subsets of PCs as well as a pathway involving sarcosine and
citrulline. These metabolic pathways may be involved in iron-induced
augmentation of IR.
AUTHOR CONTRIBUTIONS
LS e Data analysis, drafting, and writing of manuscript, SKE e data
analysis, AW, WP, AF, MS, SA, DN, UHS, BP, SZ, SR, DW, EHB, CG, ERe
patient recruitment, data acquisition and revision of manuscript for
important intellectual content, CD, TKF, EAe study concept and design,
analysis and interpretation of data, outlining, and revising themanuscript.
FINANCIAL SUPPORT
Elmar Aigner is supported by PMU Research Fund PMU-FFF (E-13/17/
086-AIG and Forschungsförderung der ÖGLMKC 2012). Support from
Figure 2: Phlebotomy study. Serum concentrations of selected metabolomics. All concentrations are mM (micromole/L). Horizontal line denotes the p-value comparing the
groups by paired t-test. Abbreviations: PC e phosphatidylcholine, PC_E e plasmalogens.
Original Article
44 MOLECULAR METABOLISM 6 (2017) 38e47  2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
Spar Austria to Christian Datz is gratefully acknowledged. The funding
sources had no involvement in the collection, analysis and interpre-
tation of data, in the writing of the report and in the decision to submit
the article for publication.
CONFLICTS OF INTEREST
None declared.
APPENDIX A. SUPPLEMENTARY DATA
Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.
molmet.2016.10.006.
REFERENCES
[1] Haslam, D.W., James, W.P., 2005. Obesity. Lancet 366(9492):1197e1209.
[2] Haynes, P., Liangpunsakul, S., Chalasani, N., 2004. Nonalcoholic fatty liver
disease in individuals with severe obesity. Clinics in Liver Disease 8:535e547.
[3] Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R.,
et al., 2003. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syn-
drome. Hepatology 37:917e923.
[4] Marceau, P., Biron, S., Hould, F.S., Marceau, S., Simard, S., Thung, S.N.,
et al., 1999. Liver pathology and the metabolic syndrome X in severe
obesity. Journal of Clinical Endocrinology and Metabolism 84:1513e1517.
[5] Knobler, H., Schattner, A., Zhornicki, T., Malnick, S.D., Keter, D.,
Sokolovskaya, N., et al., 1999. Fatty liver e an additional and treatable feature
of the insulin resistance syndrome. QJM 92:73e79.
[6] Aigner, E., Feldman, A., Datz, C., 2014. Obesity as an emerging risk factor for
iron deﬁciency. Nutrients 6:3587e3600.
[7] Ong, S.Y., Nicoll, A.J., Delatycki, M.B., 2016. How should hyper-
ferritinaemia be investigated and managed? European Journal of Internal
Medicine 33:21e27.
[8] Datz, C., Felder, T.K., Niederseer, D., Aigner, E., 2013. Iron homeostasis in
the metabolic syndrome. European Journal of Clinical Investigation 43(2):
215e224.
[9] Wrede, C.E., Buettner, R., Bollheimer, L.C., Scholmerich, J., Palitzsch, K.D.,
Hellerbrand, C., 2006. Association between serum ferritin and the insulin
resistance syndrome in a representative population. European Journal of
Endocrinology 154(2):333e340.
[10] Haap, M., Fritsche, A., Mensing, H.J., Häring, H.U., Stumvoll, M., 2003.
Association of high serum ferritin concentration with glucose intolerance
and insulin resistance in healthy people. Annals of Internal Medicine 139:
869e871.
[11] Gillum, R.F., 2001. Association of serum ferritin and indices of body fat dis-
tribution and obesity in Mexican American menethe Third National Health and
Nutrition Examination Survey. International Journal of Obesity and Related
Metabolic Disorders 25(5):639e645.
[12] Iwasaki, T., Nakajima, A., Yoneda, M., Yamada, Y., Mukasa, K., Fujita, K.,
et al., 2005. Serum ferritin is associated with visceral fat area and subcu-
taneous fat area. Diabetes Care 28(10):2486e2491.
[13] Piperno, A., Trombini, P., Gelosa, M., Mauri, V., Pecci, V., Vergani, A., et al.,
2002. Increased serum ferritin is common in men with essential hypertension.
Journal of Hypertension 20(8):1513e1518.
[14] Jehn, M., Clark, J.M., Guallar, E., 2004. Serum ferritin and risk of the
metabolic syndrome in U.S. adults. Diabetes Care 27(10):2422e2428.
[15] Martinez-Garcia, M.A., Luque-Ramirez, M., San-Millan, J.L., Escobar-
Morreale, H.F., 2009. Body iron stores and glucose intolerance in premeno-
pausal women: role of hyperandrogenism, insulin resistance, and genomic
variants related to inﬂammation, oxidative stress, and iron metabolism. Dia-
betes Care 32(8):1525e1530.
[16] Forouhi, N.G., Harding, A.H., Allison, M., Sandhu, M.S., Welch, A., Luben, R.,
et al., 2007. Elevated serum ferritin levels predict new-onset type 2 diabetes:
results from the EPIC-Norfolk prospective study. Diabetologia 50(5):949e956.
[17] Chen, X., Scholl, T.O., Stein, T.P., 2006. Association of elevated serum ferritin
levels and the risk of gestational diabetes mellitus in pregnant women: the
Camden study. Diabetes Care 29(5):1077e1082.
[18] Gastaldelli, A., Perego, L., Paganelli, M., Sesti, G., Hribal, M., Chavez, A.O.,
et al., 2009. Elevated concentrations of liver enzymes and ferritin identify a
new phenotype of insulin resistance: effect of weight loss after gastric
banding. Obesity Surgery 19:80e86.
[19] Vari, I.S., Balkau, B., Kettaneh, A., André, P., Tichet, J., Fumeron, F., et al.,
2007. Ferritin and transferrin are associated with metabolic syndrome ab-
normalities and their change over time in a general population: data from an
Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes
Care 30:1795e1801.
[20] Ellervik, C., Marott, J.L., Tybjaerg-Hansen, A., Schnohr, P., Nordestgaard, B.G.,
2014. Total and cause-speciﬁc mortality and markedly increased ferritin
concentrations: general population study and metaanalysis. Clinical Chemistry
60(11):1419e1428.
[21] Deﬁnition and diagnosis of diabetes mellitus and intermediate hyperglycemia:
report of a WHO/IDF consultation, 2006. WHO.
[22] Aigner, E., Theurl, I., Haufe, H., Seifert, M., Hohla, F., Scharinger, L., et al.,
2008. Copper availability contributes to iron perturbations in human nonal-
coholic fatty liver disease. Gastroenterology 135(2):680e688.
[23] Stadlmayr, A., Aigner, E., Steger, B., Scharinger, L., Lederer, D., Mayr, A.,
et al., 2011. Nonalcoholic fatty liver disease: an independent risk factor for
colorectal neoplasia. Journal of Internal Medicine 270(1):41e49.
[24] Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol
in Adults, 2001. Executive summary of the third report of the National
Cholesterol Education Program (NCEP) expert panel on detection, evaluation,
and treatment of high blood cholesterol in adults (adult treatment panel III).
JAMA 285:2486e2497.
[25] Neuschwander-Tetri, B.A., Caldwell, S.H., 2003. Nonalcoholic steatohepatitis:
summary of an AASLD Single Topic Conference. Hepatology 37:1202e1219.
[26] Feldman, A., Eder, S.K., Felder, T.K., Kedenko, L., Paulweber, B.,
Stadlmayr, A., et al., 2016. Clinical and metabolic characterization of lean
Caucasian subjects with non-alcoholic fatty liver. American Journal of
Gastroenterology. http://dx.doi.org/10.1038/ajg.2016.318.
[27] R Core Team, 2015. R: a language and environment for statistical computing
[Internet]. Vienna, Austria: R Foundation for Statistical Computing. Available
from: http://www.R-project.org.
[28] Xia, J., Sinelnikov, I.V., Han, B., Wishart, D.S., 2015. MetaboAnalyst
3.0dmaking metabolomics more meaningful. Nucleic Acids Research
43(W1):W251eW257.
[29] Xia, J., Mandal, R., Sinelnikov, I.V., Broadhurst, D., Wishart, D.S., 2012.
MetaboAnalyst 2.0ea comprehensive server for metabolomic data analysis.
Nucleic Acids Research 40(Web Server issue):W127eW133.
[30] Xia, J., Psychogios, N., Young, N., Wishart, D.S., 2009. MetaboAnalyst: a web
server for metabolomic data analysis and interpretation. Nucleic Acids
Research 37(Suppl 2):W652eW660.
[31] Benjamini, Y., Hochberg, Y., 1995. Controlling the false discovery rate: a
practical and powerful approach to multiple testing. Journal of Royal Statistical
Society: Series B Methodology 57(1):289e300.
[32] Livera, A.M.D., Bowne, J.B., 2014. Metabolomics: analysis of metabolomics data
[Internet]. Available from: http://CRAN.R-project.org/package¼metabolomics.
[33] Salonen, J.K., Tuomainen, T.P., Nyyssönen, K., Lakka, H.M., Punnonen, K.,
1998. Relation between iron stores and non-insulin dependent diabetes in
men: case-control study. BMJ 317(7160):727.
MOLECULAR METABOLISM 6 (2017) 38e47  2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
45
[34] Fernandez-Real, J.M., Manco, M., 2014. Effects of iron overload on chronic
metabolic diseases. Lancet Diabetes Endocrinology 2:513e526.
[35] Haap, M., Machann, J., von Friedeburg, C., Schick, F., Stefan, N.,
Schwenzer, N.F., et al., 2011. Insulin sensitivity and liver fat: role of iron
overload. J Clin Endocrinol Metab 96(6):E958eE961.
[36] Jiang, R., Ma, J., Ascherio, A., Stampfer, M.J., Willett, W.C., Hu, F.B., 2004.
Dietary iron intake and blood donations in relation to risk of type 2 diabetes in
men: a prospective cohort study. American Journal of Clinical Nutrition 79:
70e75.
[37] Houschyar, K.S., Lüdtke, R., Dobos, G.J., Kalus, U., Broecker-Preuss, M.,
Rampp, T., et al., 2012. Effects of phlebotomy-induced reduction of body iron
stores on metabolic syndrome: results from a randomized clinical trial. BMC
Medicine 10:54.
[38] Niederau, C., Berger, M., Stremmel, W., Starke, A., Strohmeyer, G., Ebert, R.,
et al., 1984. Hyperinsulinaemia in non-cirrhotic haemochromatosis: impaired
hepatic insulin degradation? Diabetologia 26(6):441e444.
[39] Davis, R.J., Corvera, S., Czech, M.P., 1986. Insulin stimulates cellular iron
uptake and causes the redistribution of intracellular transferrin receptors to the
plasma membrane. Journal of Biological Chemistry 261:8708e8711.
[40] Wang, H., Li, H., Jiang, X., Shi, W., Shen, Z., Li, M., 2014. Hepcidin is directly
regulated by insulin and plays an important role in iron overload in
streptozotocin-induced diabetic rats. Diabetes 63:1506e1518.
[41] Dongiovanni, P., Ruscica, M., Rametta, R., Recalcati, S., Steffani, L., Gatti, S.,
et al., 2013. Dietary iron overload induces visceral adipose tissue insulin
resistance. American Journal of Pathology 182(6):2254e2263.
[42] Dongiovanni, P., Valenti, L., Ludovica Fracanzani, A., Gatti, S., Cairo, G.,
Fargion, S., 2008. Iron depletion by deferoxamine up-regulates glucose uptake
and insulin signaling in hepatoma cells and in rat liver. American Journal of
Pathology 172(3):738e747.
[43] Gao, X., Zhang, W., Wang, Y., Pedram, P., Cahill, F., Zhai, G., et al., 2016.
Serum metabolic biomarkers distinguish metabolically healthy peripherally
obese from unhealthy centrally obese individuals. Nutrition Metabolism 13:33.
[44] Wuertz, P., Havulinna, A.S., Soininen, P., Tynkkynen, T., Prieto-Merino, D.,
Tillin, T., et al., 2015. Metabolite proﬁling and cardiovascular event risk: a
prospective study of 3 population-based cohorts. Circulation 131(9):774e785.
[45] Hao, D., Sarfaraz, M.O., Farshidfar, F., Bebb, D.G., Lee, C.Y., Card, C.M., et al.,
2016. Temporal characterization of serum metabolite signatures in lung
cancer patients undergoing treatment. Metabolomics 12:58.
[46] Guasch-Ferré, M., Hruby, A., Toledo, E., Clish, C.B., Martínez-González, M.A.,
Salas-Salvadó, J., et al., 2016. Metabolomics in prediabetes and diabetes: a
systematic review and meta-analysis. Diabetes Care 39:833e846.
[47] Lee, C.C., Watkins, S.M., Lorenzo, C., Wagenknecht, L.E., Il’yasova, D.,
Chen, Y.D., et al., 2016. Branched-chain amino acids and insulin meta-
bolism: the insulin resistance atherosclerosis study (IRAS). Diabetes Care
39(4):582e588.
[48] Huffman, K.M., Shah, S.H., Stevens, R.D., Bain, J.R., Muehlbauer, M.,
Slentz, C.A., et al., 2009. Relationships between circulating metabolic in-
termediates and insulin action in overweight to obese, inactive men and
women. Diabetes Care 32:1678e1683.
[49] Drogan, D., Dunn, W.B., Lin, W., Buijsse, B., Schulze, M.B., Langenberg, C.,
et al., 2015. Untargeted metabolic proﬁling identiﬁes altered serum metabo-
lites of type 2 diabetes mellitus in a prospective, nested case control study.
Clinical Chemistry 61(3):487e497.
[50] Floegel, A., Stefan, N., Yu, Z., Mühlenbruch, K., Drogan, D., Joost, H.G., et al.,
2013. Identiﬁcation of serum metabolites associated with risk of type 2 dia-
betes using a targeted metabolomic approach. Diabetes 62(2):639e648.
[51] Wang-Sattler, R., Yu, Z., Herder, C., Messias, A.C., Floegel, A., He, Y., et al.,
2012. Novel biomarkers for pre-diabetes identiﬁed by metabolomics. Molec-
ular Systems Biology 8:615.
[52] Rhee, E.P., Cheng, S., Larson, M.G., Walford, G.A., Lewis, G.D., McCabe, E.,
et al., 2011. Lipid proﬁling identiﬁes a triacylglycerol signature of insulin
resistance and improves diabetes prediction in humans. Journal of Clinical
Investigation 121(4):1402e1411.
[53] Ling, J., Chaba, T., Zhu, L.F., Jacobs, R.L., Vance, D.E., 2012. Hepatic ratio of
phosphatidylcholine to phosphatidylethanolamine predicts survival after partial
hepatectomy in mice. Hepatology 55(4):1094e1102.
[54] Li, Z., Agellon, L.B., Allen, T.M., Umeda, M., Jewell, L., Mason, A., et al., 2006.
The ratio of phosphatidylcholine to phosphatidylethanolamine inﬂuences
membrane integrity and steatohepatitis. Cell Metabolism 3(5):321e331.
[55] Ikura, Y., Ohsawa, M., Suekane, T., Fukushima, H., Itabe, H., Jomura, H.,
et al., 2006. Localization of oxidized phosphatidylcholine in nonalcoholic fatty
liver disease: impact on disease progression. Hepatology 43(3):506e514.
[56] Verkade, H.J., Fast, D.G., Rusinol, A.E., Scraba, D.G., Vance, D.E., 1993.
Impaired biosynthesis of phosphatidylcholine causes a decrease in the number
of very low density lipoprotein particles in the Golgi but not in the endoplasmic
reticulum of rat liver. Journal of Biological Chemistry 268(33):24990e24996.
[57] Yao, Z.M., Vance, D.E., 1990. Reduction in VLDL, but not HDL, in plasma of
rats deﬁcient in choline. Biochemistry and Cell Biology 68(2):552e558.
[58] Jacobs, R.L., Devlin, C., Tabas, I., Vance, D.E., 2004. Targeted deletion of
hepatic CTP: phosphocholine cytidylyltransferase alpha in mice decreases
plasma high density and very low density lipoproteins. Journal of Biological
Chemistry 279(45):47402e47410.
[59] Rinella, M.E., Elias, M.S., Smolak, R.R., Fu, T., Borensztajn, J., Green, R.M.,
2008. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine
choline-deﬁcient diet. Journal of Lipid Research 49(5):1068e1076.
[60] Noga, A.A., Vance, D.E., 2003. A genderspeciﬁc role for phosphatidyletha-
nolamine N-methyltransferase-derived phosphatidylcholine in the regulation of
plasma high density and very low density lipoproteins in mice. Journal of
Biological Chemistry 278(24):21851e21859.
[61] Jacobs, R.L., Zhao, Y., Koonen, D.P., Sletten, T., Su, B., Lingrell, S., et al., 2010.
Impaired de novo choline synthesis explains why phosphatidylethanolamine N-
methyltransferase-deﬁcient mice are protected from diet-induced obesity. Journal
of Biological Chemistry 285(29):22403e22413.
[62] Li, Z., Agellon, L.B., Vance, D.E., 2005. Phosphatidylcholine homeostasis and
liver failure. Journal of Biological Chemistry 280(45):37798e37802.
[63] Sreekumar, A., Poisson, L.M., Rajendiran, T.M., Khan, A.P., Cao, Q., Yu, J.,
et al., 2009. Metabolomic proﬁles delineate potential role for sarcosine in
prostate cancer progression. Nature 457:910e914.
[64] Issaq, H.J., Waybright, T.J., Veenstra, T.D., 2011. Cancer biomarker discovery:
opportunities and pitfalls in analytical methods. Electrophoresis 32:967e975.
[65] Cavaliere, B., Macchione, B., Monteleone, M., Naccarato, A., Sindona, G.,
Tagarelli, A., 2011. Sarcosine as a marker in prostate cancer progression: a
rapid and simple method for its quantiﬁcation in humane urine by solide-phase
microextraction-gas chromatography-triple quadrupole mass spectroscopy.
Analytical and Bioanalytical Chemistry 400:2903e2912.
[66] Mukherjee, S., Cruz-Rodriguez, O., Bolton, E., Iniguez-Lluhi, J.A., 2012. The
in vivo role of androgen receptor SUMOylation as revealed by androgen
insensitivity syndrome and prostate cancer mutations targeting the proline/
glycine residues of synergy control motifs. Journal of Biological Chemistry 287:
31195e31206.
[67] Cernei, N., Heger, Z., Gumulec, J., Zitka, O., Masarik, M., Babula, P., et al., 2013.
Sarcosine as a potential prostate cancer biomarker e a review. International
Journal of Molecular Sciences 14:13893e13908.
[68] Jegatheesan, P., Beutheu, S., Ventura, G., Sarfati, G., Nubret, E., Kapel, N.,
et al., 2016. Effect of speciﬁc amino acids on hepatic lipid metabolism in
fructose-induced non-alcoholic fatty liver disease. Clinical Nutrition 35(1):
175e182.
[69] Jegatheesan, P., Beutheu, S., Ventura, G., Nubret, E., Sarfati, G., Bergheim, I.,
et al., 2015. Citrulline and nonessential amino acids prevent fructose-induced
nonalcoholic fatty liver disease in rats. Journal of Nutrition 145:2273e2279.
[70] Moinard, C., Le Plenier, S., Noirez, P., Morio, B., Bonnefont-Rousselot, D.,
Kharchi, C., et al., 2015. Citrulline supplementation induces changes in body
Original Article
46 MOLECULAR METABOLISM 6 (2017) 38e47  2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
composition and limits age-related metabolic changes in healthy male rats.
Journal of Nutrition 145(7):1429e1437.
[71] Jofﬁn, N., Jaubert, A.M., Durant, S., Bastin, J., De Bandt, J.P., Cynober, L.,
et al., 2014. Citrulline induces fatty acid release selectively in visceral adipose
tissue from old rats. Molecular Nutrition and Food Research 58:1765e1775.
[72] Breuillard, C., Cynober, L., Moinard, C., 2015. Citrulline and nitrogen
homeostasis: an overview. Amino Acids 47:685e691.
[73] Cox, M., Lehninger, A.L., Nelson, D.R., 2000. Lehninger principles of
biochemistry, 3rd ed. New York: Worth Publishers. ISBN 1-57259-153-6.
[74] Seidner, D.L., Joly, F., Youssef, N.H., 2015. Effect of teduglutide, a glucagon-
like peptide 2 analog, on citrulline levels in patients with short bowel syndrome
in two phase III randomized trials. Clinical and Translational Gastroenterology
6:e93.
MOLECULAR METABOLISM 6 (2017) 38e47  2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
47
